This is a summary of the European public assessment report (EPAR) for Terrosa. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Terrosa. For practical information about using Terrosa, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Terrosa is indicated in adults. Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non vertebral fractures but not hip fractures has been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.
Therapeutic Area (MeSH)
ATC Code
H05AA02
ATC Item
teriparatide
Pharmacotherapeutic Group
Calcium homeostasis
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| teriparatide | N/A | 特立帕肽 |
EMA Name
Terrosa
Medicine Name
Terrosa
Aliases
N/A